Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.33 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.33 |
| ▸ | CNR1 | P21554 | 1/20 | 0.32 |
| ▸ | CNR2 | P34972 | 1/20 | 0.32 |
| ▸ | MMP13 | P45452 | 1/20 | 0.32 |
| ▸ | PTGER4 | P35408 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | THRB | P10828 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24813943 | 0.86 | CHRM2 (0.36) | CHRM2CHRM4CHRM5CHRM3CNR1 | |
| SCHEMBL24007224 | 0.85 | CHRM2 (0.33) | CHRM2CHRM4CHRM5CHRM3CNR1 | |
| SCHEMBL24007544 | 0.85 | CHRM2 (0.33) | MAP3K14CHRM2CHRM4CHRM5CHRM3 | |
| SCHEMBL24008003 | 0.83 | PTGER4 (0.30) | MAP3K14PTGER4ALDH1A1L3MBTL1 | |
| SCHEMBL21961347 | 0.81 | L3MBTL1 (0.40) | MAP3K14CHRM2CHRM4CHRM5CHRM3 | |
| SCHEMBL24816265 | 0.80 | CNR2 (0.40) | MAP3K14CNR1CNR2 | |
| SCHEMBL25745822 | 0.79 | MAP3K14 (0.37) | MAP3K14CNR1CNR2 | |
| SCHEMBL24007024 | 0.79 | CNR1 (0.40) | CNR1CNR2ALDH1A1KDM4E | |
| SCHEMBL21960872 | 0.75 | MAP3K14 (0.34) | MAP3K14CHRM2CHRM4CHRM5CHRM3 | |
| SCHEMBL25745824 | 0.71 | CNR1 (0.41) | CNR1CNR2ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11691963-B2 | 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors | AJAX THERAPEUTICS, INC. (US) | 2023-07-04 | — | — | US | disclosed |
| US-11691963-B2 | 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors | AJAX THERAPEUTICS, INC. (US) | 2023-07-04 | — | — | US | disclosed |
| US-20220411403-A1 | 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS | AJAX THERAPEUTICS, INC. | 2022-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220411403-A1 | 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS | JAK2, JAK3, STAT5B | MAP3K14 564/4885CHRM2 4880/4885CHRM4 4875/4885 |
| US-11691963-B2 | 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors | JAK2, JAK3, STAT5B | MAP3K14 564/4885CHRM2 4880/4885CHRM4 4875/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.